AstraZeneca (AZN) Given “Hold” Rating at Liberum Capital
AstraZeneca (LON:AZN)‘s stock had its “hold” rating reissued by research analysts at Liberum Capital in a report issued on Friday.
Several other research analysts have also commented on AZN. UBS Group reaffirmed a “neutral” rating and issued a GBX 5,900 ($77.09) price target on shares of AstraZeneca in a report on Monday, November 19th. JPMorgan Chase & Co. reaffirmed an “overweight” rating on shares of AstraZeneca in a report on Monday, November 19th. Barclays reaffirmed an “overweight” rating and issued a GBX 6,800 ($88.85) price target on shares of AstraZeneca in a report on Monday, November 19th. Shore Capital reaffirmed a “hold” rating on shares of AstraZeneca in a report on Tuesday, October 30th. Finally, BNP Paribas set a GBX 6,500 ($84.93) price target on shares of AstraZeneca and gave the company a “buy” rating in a report on Tuesday, September 11th. Two research analysts have rated the stock with a sell rating, eight have given a hold rating and eleven have issued a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average target price of GBX 5,927.44 ($77.45).
LON AZN opened at GBX 5,955 ($77.81) on Friday. AstraZeneca has a one year low of GBX 4,260 ($55.66) and a one year high of GBX 5,520 ($72.13).
AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
Read More: Understanding Analyst Ratings
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.